Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 13/20 | 0.63 |
| ▸ | SYK | P43405 | 13/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.63 |
| ▸ | GSK3A | P49840 | 10/20 | 0.61 |
| ▸ | LCK | P06239 | 2/20 | 0.60 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.55 |
| ▸ | TNF | P01375 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6842582 | 0.92 | GSK3A (0.53) | SRCSYKMAPK14GSK3A | |
| SCHEMBL6547102 | 0.86 | GSK3A (0.64) | SRCSYKMAPK14GSK3ALCK | |
| SCHEMBL6546016 | 0.85 | GSK3A (0.61) | SRCSYKMAPK14GSK3ALCK | |
| SCHEMBL6545942 | 0.84 | SRC (0.61) | SRCSYKMAPK14GSK3ALCK | |
| SCHEMBL6545943 | 0.84 | GSK3A (0.67) | SRCSYKMAPK14GSK3ALCK | |
| SCHEMBL6546622 | 0.84 | GSK3A (0.65) | SRCSYKMAPK14GSK3ALCK | |
| SCHEMBL17659974 | 0.84 | GSK3A (0.74) | SRCSYKMAPK14GSK3ALCK | |
| SCHEMBL6547269 | 0.83 | GSK3A (0.61) | SRCSYKMAPK14GSK3ALCK | |
| SCHEMBL6546583 | 0.83 | GSK3A (0.60) | SRCSYKMAPK14GSK3ALCK | |
| SCHEMBL6841056 | 0.82 | MAPK14 (0.63) | SRCSYKMAPK14GSK3ALCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6765009-B2 | N-(5-TERT-BUTYL-3-(3-(4-((2-DIMETHYLAMINOMETHYL-PYRIDIN-4-YL) -PIPERAZIN-1-YL-METHYL) NAPHTHALEN-1-YL)UREIDO)-2-METHOXYPHENYL) METHANESULFONAMIDE FOR EXAMPLE; CYTOKINE INHIBITORS FOR TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-07-20 | — | — | US | disclosed |